Compare ATEN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | COLL |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2014 | 2015 |
| Metric | ATEN | COLL |
|---|---|---|
| Price | $17.49 | $46.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $21.50 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 734.7K | 483.2K |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 4.68 | N/A |
| EPS | 0.69 | ★ 1.63 |
| Revenue | $284,406,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $12.37 | $26.35 |
| Revenue Next Year | $8.10 | $3.67 |
| P/E Ratio | ★ $25.42 | $28.10 |
| Revenue Growth | 10.27 | ★ 26.34 |
| 52 Week Low | $13.81 | $23.23 |
| 52 Week High | $21.90 | $50.79 |
| Indicator | ATEN | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 46.54 |
| Support Level | $17.21 | $44.51 |
| Resistance Level | $17.98 | $50.79 |
| Average True Range (ATR) | 0.34 | 1.36 |
| MACD | -0.09 | -0.66 |
| Stochastic Oscillator | 19.53 | 29.95 |
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.